Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Capecitabine|DRUG: Talazoparib|DRUG: Pembrolizumab|DRUG: Inavolisib
Sponsor: Bryan Schneider, MD
Collaborators: Genentech, Inc.|Pfizer|Foundation Medicine|Indiana University|Vera Bradley Foundation for Breast Cancer Research